Kodiak Sciences Inc. develops retinal medicines as a precommercial biotechnology company focused on diseases that can cause vision loss. News about KOD centers on the ABC Platform and ABCD Platform, the anti-VEGF biologic Zenkuda (tarcocimab tedromer), and bispecific programs including KSI-501 and KSI-101.
Recurring updates cover clinical data in diabetic retinopathy, wet age-related macular degeneration and macular edema secondary to inflammation, along with scientific conference presentations, financial results and capital formation. Company announcements also discuss pipeline expansion into multi-target retinal and ocular disease approaches, including programs directed at inflammation, geographic atrophy and glaucoma optic neuropathy.
Kodiak Sciences (Nasdaq: KOD) announced the completion of enrollment in its GLOW Phase 3 clinical trial for tarcocimab tedromer (KSI-301), targeting non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema. This investigational therapy aims to provide significant treatment opportunities by potentially extending administration intervals to six months, addressing the treatment burden of current therapies. The trial involves approximately 240 patients, with primary results expected in a year.
Kodiak Sciences Inc. (Nasdaq: KOD) will present at the Jefferies Global Healthcare Conference on June 9, 2022, at 11:30 a.m. PT. The live webcast will be accessible on Kodiak's website and available for replay after the event. Kodiak focuses on developing therapies for retinal diseases and is known for its ABC Platform™, which combines antibody-based and chemistry-based therapies. Their lead candidate, KSI-301, targets retinal vascular diseases. More about Kodiak can be found on their website.
Kodiak Sciences Inc. (Nasdaq: KOD) and Lonza have inaugurated a bioconjugation facility in Lonza's Ibex® Dedicate Biopark in Switzerland. This facility will support the potential commercial launch of KSI-301, Kodiak's lead product for retinal diseases. Expected to produce over 10 million doses annually, the facility strengthens collaboration between Kodiak and Lonza, creating 12 new jobs at Kodiak and 70 at Lonza. KSI-301 is currently undergoing Phase 3 trials for multiple retinal conditions, with plans to file a Biologics License Application pending successful results.
Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q1 2022 results with a net loss of $95.7 million ($1.83 per share), increasing from a net loss of $50.4 million in Q1 2021. R&D expenses rose to $76.2 million due to clinical trial costs and manufacturing activities. Despite challenges in its Phase 2b/3 wet AMD study, Kodiak remains optimistic about its KSI-301 program, anticipating four Phase 3 study readouts in 2022 and 2023. The company ended the quarter with $671.7 million in cash, maintaining a strong cash position for ongoing developments.
Kodiak Sciences Inc. (Nasdaq: KOD) announced that it will present clinical study data for its investigational therapy KSI-301 at two major vision research conferences. Key presentations include results from the Phase 2b/3 DAZZLE study focused on the efficacy and safety of KSI-301 in wet age-related macular degeneration (AMD). The presentations will take place at the ARVO 2022 Annual Meeting on May 3 and at Retina World Congress 2022 on May 13. KSI-301 aims to provide enhanced durability and efficacy for treating retinal diseases.
Kodiak Sciences Inc. (Nasdaq: KOD) reported Q4 2021 financial results, with a net loss of $93.2 million, up from $46.6 million a year earlier. The company’s Phase 2b/3 study of KSI-301 in wet AMD did not meet primary efficacy endpoints, although it demonstrated potential safety and extended dosing for 59% of patients. R&D expenses surged to $75.6 million, reflecting increased clinical trial costs. Kodiak maintains a strong cash position of $731.5 million, with key upcoming studies expected to yield top-line data in 2022, including the BEACON study.
Kodiak Sciences (Nasdaq: KOD) announced top-line results from its Phase 2b/3 trial of KSI-301, aimed at treating neovascular age-related macular degeneration. The trial, involving 559 participants, showed that while KSI-301 was safe and demonstrated durability, it did not meet its primary efficacy endpoint of non-inferior visual acuity gains compared to aflibercept. However, 59% of KSI-301 patients achieved five-month dosing with comparable visual and anatomical improvements. The company is optimistic about ongoing studies, including BEACON and DAYLIGHT, to clarify the role of KSI-301 in retinal diseases.
Kodiak Sciences (Nasdaq: KOD) announced the completion of enrollment in its Phase 3 clinical trials, GLEAM and GLIMMER, for KSI-301, an anti-VEGF antibody biopolymer conjugate targeting diabetic macular edema (DME). These pivotal trials aim to assess KSI-301's efficacy in providing long-lasting treatment, with doses as infrequent as every six months. Kodiak also reports progress in additional studies, including GLOW, DAZZLE, and BEACON, aimed at supporting a broad Biologics License Application (BLA) for multiple retinal diseases. Topline results are anticipated soon.
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 11:15 a.m. PT. The event will focus on the company's innovative therapeutics for retinal diseases, utilizing its ABC Platform™. A live webcast will be available on Kodiak's website, allowing access for a limited time post-event.
Kodiak aims to develop transformative medicines, with its lead candidate, KSI-301, targeting age-related macular degeneration and other retinal vascular diseases.
Kodiak Sciences (Nasdaq: KOD) has successfully completed enrollment in its BEACON Phase 3 clinical trial for KSI-301, an investigational anti-VEGF therapy targeting macular edema from retinal vein occlusion (RVO). The trial includes over 550 patients and aims to assess KSI-301's efficacy and durability compared to monthly aflibercept dosing. Results are expected in the first quarter of the upcoming year, with the potential to improve treatment options for vision loss caused by RVO.